BioFocus DPI Expands Its Drug Discovery Offering With Proteomics Technology From Activiomics
7/25/2012 10:18:31 AM
SAFFRON WALDEN, England--(BUSINESS WIRE)--BioFocus and Activiomics today announced a strategic alliance which will allow BioFocus to offer Activiomics’ proteomics services to its customers, to improve identification of novel targets for drug discovery and biomarkers for diagnostics. Activiomics’ proprietary technology, TIQUAS (Targeted In-depth QUAntification of cell Signaling), provides valuable insights into which proteins or pathways have been activated following a cell signaling event, information that is generally not accessible using conventional expression analysis. This has application in a range of therapeutic areas including oncology, inflammation and metabolic disease.